Provided By GlobeNewswire
Last update: Oct 11, 2023
-- High neutralizing antibody (nAb) responses sustained through at least 12 months, highlighting potential for durable clinical protection --
-- T cell responses to Spike plus other viral targets observed in all Phase 1 studies, demonstrating broad and potentially variant-proof immune response --
Read more at globenewswire.com